What is DECIDER? DECIDER, or "Clinical Decision via Integrating Multiple Data Levels to Overcome Chemotherapy Resistance in High-Grade Serous Ovarian Cancer" is a research project funded by the EU under Horizon 2020 research and innovation programme.

Who are the members? DECIDER consortium has 14 participants, of which 10 academic members and 4 companies. The project is coordinated by the University of Helsinki (prof. S. Hautaniemi), and has participants from Finland, Sweden, Denmark, Spain, Germany and Italy.

What is DECIDER about? Ovarian cancer kills more than 44,000 women in Europe every year due to lack of effective and long-lasting therapeutic regimens. DECIDER presents an innovative strategy to suggest effective treatments that lead to a marked decrease in ovarian cancer deaths and reduce the number of expensive but inefficient treatments. Our approach paves the way to move beyond the current trial-and-error clinical assessment of drug combinations toward more systematic prediction of the most effective treatments for each patient. The proposed concept will be a major breakthrough in personalised medicine and will benefit individual patients and the health-care system through more effective treatments, and the diagnostic and pharmaceutical industry through tools for better stratified clinical trials, and novel treatment and diagnostic modalities. [text from DECIDER application abstract]

When is this happening? We started in March 2021. The project is planned to last for 5 years. The total funding is 15M €, of that for the GenomeDataLab 1M €. We are very grateful for the support!

What is the role of GenomeDataLab in DECIDER? We lead the Work-package 4 "Longitudinal data and tumour evolution analysis" and participate in the Work-package 7 "In vitro and in vivo validation".

Here is a visual summary of the plans for GenomeDataLab participation in DECIDER:

For more information, head to https://www.deciderproject.eu/, or follow the @ProjectDecider twitter.